Security
GRCE · Grace Therapeutics, Inc.
GRCENASDAQCommon stockCurrentCIK 1444192Updated Sep 29, 2026
Name history
Acasti Pharma Inc. · through Oct 25, 2024
GRCE price & chart
Loading TradingView…
NASDAQ:GRCE on TradingView ↗About the company
Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE ↗
Recent filings
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 66,654,000Source | 71,993,000Source | 73,300,000Source | 79,123,000Source |
| Property, Plant and Equipment, NetUSD | 8,000Source | 15,000Source | 24,000Source | 12,198,000Source |
| GoodwillUSD | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 41,128,000Source | 41,128,000Source | 41,128,000Source | 41,128,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 16,977,000Source | 22,133,000Source | 23,005,000Source | 27,875,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 722,000Source | 802,000Source |
| Assets, CurrentUSD | 17,380,000Source | 22,712,000Source | 24,010,000Source | 29,290,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 0Source | 463,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,758,000Source | 5,383,000Source | 11,557,000Source | 11,168,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | — | 258,294,000Source |
| Additional Paid in CapitalUSD | 298,413,000Source | 293,334,000Source | 17,862,000Source | 13,965,000Source |
| Retained Earnings (Accumulated Deficit)USD | -228,480,000Source | -220,687,000Source | -211,119,000Source | -198,266,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -6,038,000Source | -6,038,000Source | -6,038,000Source | -6,038,000Source |
| Stockholders' Equity Attributable to ParentUSD | 63,896,000Source | 66,610,000Source | 61,743,000Source | 67,955,000Source |
| Liabilities and EquityUSD | 66,654,000Source | 71,993,000Source | 73,300,000Source | 79,123,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,146,000Source | 1,930,000Source | 1,684,000Source | 3,411,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | 0Source | 75,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 0Source | 410,000Source |
| Deferred Income Tax Liabilities, NetUSD | 612,000Source | 2,312,000Source | 5,514,000Source | 7,347,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | — | 176,000Source | 946,000Source |
| Deferred Tax Liabilities, NetUSD | 612,000Source | — | — | — |
| Short-term InvestmentsUSD | — | — | 0Source | 15,000Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 798,000Source | 730,000Source | 913,000Source | 1,811,000Source |
| Deferred Income Tax Expense (Benefit)USD | -1,700,000Source | -3,202,000Source | -1,834,000Source | -9,542,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,869,000Source | -14,904,000Source | -12,333,000Source | -15,913,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | 0Source | 104,000Source | 13,153,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 3,713,000Source | 14,032,000Source | 7,359,000Source | 304,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -5,156,000Source | -872,000Source | -4,870,000Source | -2,464,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 16,977,000Source | 22,133,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 12,000Source | — | — | — |
| Additional Financial Items | ||||
| DepreciationUSD | 7,000Source | 7,000Source | 11,000Source | 124,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -1,000Source | -17,000Source | -16,000Source | -72,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | 0Source | -5,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | -39,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 0Source | 59,000Source | — |
| General and Administrative ExpenseUSD | 8,672,000Source | 7,168,000Source | 6,432,000Source | 7,614,000Source |
| GoodwillUSD | 8,138,000Source | 8,138,000Source | 8,138,000Source | 8,138,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | 28,682,000Source |
| Income Tax Expense (Benefit)USD | -1,700,000Source | -3,199,000Source | -1,832,000Source | -9,542,000Source |
| Investment Income, InterestUSD | 685,000Source | 711,000Source | 911,000Source | 246,000Source |
| Net Income (Loss) Attributable to ParentUSD | -7,793,000Source | -9,568,000Source | -12,853,000Source | -42,429,000Source |
| Nonoperating Income (Expense)USD | 1,584,000Source | 3,912,000Source | -1,833,000Source | 184,000Source |
| Operating Lease, ExpenseUSD | — | — | 93,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | 0Source | 304,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 0Source | — | — |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -11,077,000Source | -16,679,000Source | -12,852,000Source | -52,155,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -9,493,000Source | -12,767,000Source | -14,685,000Source | -51,971,000Source |
| Income Tax Expense (Benefit)USD | -1,700,000Source | -3,199,000Source | -1,832,000Source | -9,542,000Source |
| Net Income (Loss) Attributable to ParentUSD | -7,793,000Source | -9,568,000Source | -12,853,000Source | -42,429,000Source |
| Earnings Per Share, BasicUSD per share | -0.47Source | -0.79Source | -1.35Source | -0.95Source |
| Earnings Per Share, DilutedUSD per share | -0.47Source | -0.79Source | -1.35Source | -0.95Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 16,510,632Source | 12,087,270Source | 9,529,123Source | 44,612,831Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 16,510,632Source | 12,087,270Source | 9,529,123Source | 44,612,831Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 3,000Source | 2,000Source | 0Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | -1,000Source | -17,000Source | -16,000Source | -72,000Source |
| General and Administrative ExpenseUSD | 8,672,000Source | 7,168,000Source | 6,432,000Source | 7,614,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Investment Income, InterestUSD | 685,000Source | 711,000Source | 911,000Source | 246,000Source |
| Nonoperating Income (Expense)USD | 1,584,000Source | 3,912,000Source | -1,833,000Source | 184,000Source |
| Operating Lease, ExpenseUSD | — | — | 93,000Source | — |
| Other IncomeUSD | — | — | — | 0Source |
| Research and Development ExpenseUSD | 2,405,000Source | 9,511,000Source | 4,683,000Source | 9,972,000Source |
| Restructuring and Related Cost, Incurred CostUSD | — | 0Source | 1,485,000Source | — |
| Selling and Marketing ExpenseUSD | — | — | 252,000Source | 661,000Source |
Filing attachments
ef20079525_ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ef20079525_ex99-1.htm EXHIBIT 99.1 Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE) - Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today ann…
Read attachment ↗ef20079559_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 4 ef20079559_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces $10 Million Private Placement Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028 PRINCETON, N.J., August 4, 2026 - Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address signi…
Read attachment ↗ef20078866_ex99-1.htm · 8-K · 2026-07-28
EX-99.1 2 ef20078866_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission Princeton, NJ, July 28, 2026 (GLOBE NEWSWIRE) - Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the…
Read attachment ↗ef20078866_ex99-2.htm · 8-K · 2026-07-28
EX-99.2 3 ef20078866_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Corporate Presentation Late Summer 2026 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and "forward-loo…
Read attachment ↗ef20076431_ex99-1.htm · 8-K · 2026-06-18
EX-99.1 2 ef20076431_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Corporate Presentation June 2026 Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and "forward-looking inf…
Read attachment ↗ef20076145_ex99-1.htm · 8-K · 2026-06-18
EX-99.1 2 ef20076145_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Resubmission for GTx-104 for the Treatment of Patients with aSAH P…
Read attachment ↗